Veradermics, Inc. (MANE) Annual Report: A Plain-English Guide

I wrote this guide to help you understand Veradermics’ performance. My goal is to explain their progress and financial health clearly, so you can decide if this company fits your portfolio without wading through dense jargon.

1. What does this company do?

Veradermics is a biotech company based in New Haven, CT, focused on treating pattern hair loss. They currently have no products on the market. Their main project is VDPHL01, an oral, non-hormonal pill designed to grow hair without the hormonal side effects associated with treatments like finasteride.

2. The Big Milestone: Going Public

As of March 2026, Veradermics trades under the ticker MANE with 37.3 million shares outstanding. They raised $115 million in their IPO at $12.00 per share. These funds are earmarked to cover Phase 2b and Phase 3 clinical trials and daily operations through 2027.

3. Progress on the Science

The company is currently testing VDPHL01 in two large Phase 2b studies involving 1,050 men, with results expected in late 2026. They have also initiated a smaller study for 200 women.

Early results are promising: in a pilot study of 21 men, 90.5% saw improved hair coverage after 16 weeks. While these results are encouraging, the company must now replicate this success in larger trials to secure FDA approval.

4. Financial Health: The "Burn"

Because the company is still in the development phase, it does not yet generate profit.

• The Reality: In 2025, Veradermics lost $42.8 million, primarily driven by research and development costs. By the end of the year, they held $88.2 million in cash.
• The Risk: With a quarterly burn rate of approximately $10.7 million, current cash reserves are projected to last until late 2027. To fund later-stage trials, the company will likely issue more shares, which would dilute your ownership percentage.

5. What to Watch (The Risks)

Investing in Veradermics is a high-stakes proposition. Because the company relies entirely on the success of a single drug, an FDA rejection could lead to a total loss of your investment. Other key risks include:

• The "Cash-Pay" Gamble: The company plans to sell directly to consumers for $80–$120 per month. Their profitability depends on their ability to attract and retain customers at this price point.
• Manufacturing: Veradermics relies on third-party manufacturers. Any failure by these partners to meet quality standards could result in supply shortages or regulatory delays.
• Intellectual Property: The company’s value is tied to its patents. If these patents are challenged or if a competitor develops a superior treatment, the company’s market advantage would be significantly compromised.

6. The Bottom Line

Veradermics is a high-risk, high-reward investment. They have a clear goal and positive early data, but they are far from being a stable, established business. You are essentially betting on the success of one drug. Expect the stock price to be volatile as the market reacts to the upcoming 2026 trial results.

Investor Tip: Before investing, consider whether your portfolio can handle the volatility of a "single-asset" biotech company. If you are looking for stability, this may not be the right fit; if you are looking for high-growth potential and are comfortable with the risk of a total loss, keep a close eye on the 2026 clinical trial data.